Clinical Trial Update: Safety and Pharmacodynamics of SEL-068 Vaccine in Smokers and Non-Smokers [Phase 1]

View source ↗

Summary

Phase 1 results indicate safety and pharmacodynamic effects of the SEL-068 vaccine in both smokers and non-smokers, with the trial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence

Drugs mentioned

• SEL-068 (SEL-068 vaccine)

Snippet

Sponsor: Selecta Biosciences, Inc. | Conditions: Smoking Cessation | Phase 1 | Status: COMPLETED